CD7-Negative T Cell Preparation via Two-Step Selection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating relapsed/refractory hematological malignancies, such as T-ALL and AML, face challenges in targeting CD7 antigens due to fratricide issues with CD7 CAR T cells and the lack of a widely expressed antigen on T-ALL cells, necessitating improved isolation and genetic modification techniques for CD7-negative T cells.
Innovation Solution
A two-step selection method using immunoaffinity-based techniques to deplete CD7-positive and enrich CD3-positive T cells, followed by stimulation and genetic modification to create CD7-negative, CD3-positive T cells expressing chimeric antigen receptors, which are then used for adoptive immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CD7 CAR T cells are used to target CD7+ leukemia cells, then anti-leukemia activity is improved, but fratricide occurs reducing T cell viability
Solution Approach 1:
The patent extracts and removes CD7+ T cells from the starting population through depletion, isolating only CD7- T cells for CAR transduction. This extraction of the harmful component (CD7+ cells that would undergo fratricide) resolves the contradiction by enabling anti-leukemia activity without self-destruction.
Solution Approach 2:
Instead of using CD7+ T cells as conventional approach, the patent inverts the selection by using CD7- T cells. This inversion changes the paradigm from targeting CD7+ cells with CD7+ T cells (which causes fratricide) to targeting CD7+ leukemia cells with CD7- T cells (which avoids fratricide).
2Manufacturing precision
If a two-step selection method is used to isolate CD7-negative T cells, then purity of CD7-negative population is improved, but process complexity increases
Solution Approach 1:
The patent segments the selection process into two distinct steps: first depleting CD7+ cells, then enriching for CD3+ T cells. This segmentation allows each step to be optimized independently and performed using standard, readily available reagents and procedures, making the complex process manageable and scalable.
Solution Approach 2:
The patent performs preliminary depletion of CD7+ cells before enrichment of CD3+ T cells. This preliminary action ensures that the enrichment step works on a pre-filtered population, improving overall efficiency and reducing the complexity of achieving high purity in a single step.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method generates a predominantly CD4+ effector memory T cell population with potent anti-leukemia activity in vitro and in vivo, providing a viable source for cancer immunotherapy by specifically targeting CD7+ leukemia cells without fratricide.
Implementation Method 1
contacting the population of primary human immune cells with a first immunoaffinity reagent that specifically binds to CD7 on the surface of the primary human immune cells
Implementation Method 2
contacting the population of CD7-negative cells with a second immunoaffinity reagent that specifically binds to CD3 on the surface of the CD7-negative cells
Data Source
AI summary
Methods for preparing CD7-negative, CD3-positive T cells, which optionally express a chimeric antigen receptor, are provided as is a method of using such cells in a method for treating cancer, in particular a CD7+ cancer. In one aspect, the invention provides a method for preparing a population of CD7-negative, CD3-positive T cells by (a) performing a first selection by depleting, from a population of primary immune cells, cells that express CD7 thereby generating a population of CD7-negative cells; (b) performing a second selection by enriching, from the population of CD7-negative cells, T cells that express CD3 thereby generating a population of CD7-negative and CD3-positive T cells, and (c) incubating the population of CD7-negative and CD3-positive T cells in a culture vessel under stimulating conditions, thereby generating stimulated CD7-negative, CD3-positive T cells.